AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12374440 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive role models for promotion-focused individuals
Number of subjects: 0
Study 12374440 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative role models for prevention-focused individuals
Number of subjects: 0
Study 12374440 — intervention group
Group type: COMPARATOR
Intervention: Goal-incongruent role models
Number of subjects: 0
Study 12374440 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-congruent role models
Number of subjects: 0
Study 12374440 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-life role models matching chronic goals
Number of subjects: 0
Study 9935020 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 6.25 mg increasing to 50 mg t.d.s. after intravenous streptokinase
Number of subjects: 493
Study 9935020 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril in anterior infarction with TIMI 0-2 flow
Number of subjects: 493
Study 9935020 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril in anterior infarction with corrected TIMI frame counts > 27
Number of subjects: 493
Study 9935020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 493
Study 7561799 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral brivudin (125 mg tablet every 6 hours for 5 days)
Number of subjects: 48
Study 7561799 — intervention group
Group type: COMPARATOR
Intervention: Intravenous acyclovir (10 mg/kg infused over 1 hour every 8 hours for 5 days)
Number of subjects: 48
Study 7561799 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral brivudin
Number of subjects: 48
Study 7561799 — intervention group
Group type: COMPARATOR
Intervention: Intravenous acyclovir
Number of subjects: 48
Study 2222030 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous needle aspiration with drugs (metronidazole, diloxanide, chloroquine)
Number of subjects: 36
Study 2222030 — intervention group
Group type: COMPARATOR
Intervention: Drugs alone (metronidazole, diloxanide, chloroquine)
Number of subjects: 36
Study 2222030 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous needle aspiration
Number of subjects: 36
Study 2222030 — intervention group
Group type: COMPARATOR
Intervention: Drugs alone (non-aspirated group)
Number of subjects: 36
Study 319319 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 4200
Study 319319 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 4200
Study 31285082 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2, carboplatin AUC 6 mg/mL/min, and bevacizumab 15 mg/kg every 21 days until disease progression, complete remission, or limiting toxicity.
Number of subjects: 34
Study 31285082 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel, carboplatin, and bevacizumab treatment
Number of subjects: 34
Study 29195602 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocytapheresis (treatment group)
Number of subjects: 104
Study 29195602 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment by plasmapheresis (control group)
Number of subjects: 104
Study 25644578 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.20 ml local anaesthetic per mm² cross-sectional nerve area (starting volume)
Number of subjects: 0
Study 25644578 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02 ml.mm(‐2) reduction in local anaesthetic volume if surgical anaesthesia was adequate
Number of subjects: 0
Study 24381278 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenitally blind participants
Number of subjects: 0
Study 24381278 — intervention group
Group type: COMPARATOR
Intervention: Sighted participants
Number of subjects: 0
Study 24381278 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI analysis in both groups
Number of subjects: 0
Study 24381278 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural similarity matrices of IT and OSC
Number of subjects: 0
Study 21647577 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (AMP) 10 mg and 20 mg
Number of subjects: 0
Study 21647577 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ(9)-tetrahydrocannabinol (THC) 7.5 mg and 15 mg
Number of subjects: 0
Study 21647577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19512873 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (4 mg/kg)
Number of subjects: 52
Study 19512873 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 52
Study 19512873 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 52
Study 17449580 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.2 g/d CLA
Number of subjects: 48
Study 17449580 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.4 g/d CLA
Number of subjects: 48
Study 17449580 — intervention group
Group type: COMPARATOR
Intervention: Placebo (8 g safflower oil/d)
Number of subjects: 48
Study 14730384 — intervention group
Group type: EXPERIMENTAL
Intervention: MnDPDP-enhanced MRI
Number of subjects: 44
Study 14730384 — intervention group
Group type: EXPERIMENTAL
Intervention: Unenhanced MRI
Number of subjects: 44
Study 14730384 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiral CT
Number of subjects: 44
Study 15335109 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 9000
Study 15335109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9000
Study 11681160 — intervention group
Group type: EXPERIMENTAL
Intervention: International Classification of Primary Care (ICPC)
Number of subjects: 0
Study 11681160 — intervention group
Group type: COMPARATOR
Intervention: Read Clinical Codes, version II
Number of subjects: 0
Study 9655716 — intervention group
Group type: EXPERIMENTAL
Intervention: HEPA air cleaner
Number of subjects: 35
Study 9655716 — intervention group
Group type: COMPARATOR
Intervention: Placebo air cleaner
Number of subjects: 35
Study 8186134 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 1% cream applied twice daily for 1 week
Number of subjects: 211
Study 8186134 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole 1% cream applied twice daily for 4 weeks
Number of subjects: 211
Study 3130124 — intervention group
Group type: EXPERIMENTAL
Intervention: Polaroid prints from a non-mydriatic fundus camera
Number of subjects: 127
Study 3130124 — intervention group
Group type: COMPARATOR
Intervention: 35 mm transparencies
Number of subjects: 127
Study 3130124 — intervention group
Group type: COMPARATOR
Intervention: Fluorescein angiograms
Number of subjects: 127
Study 3130124 — intervention group
Group type: EXPERIMENTAL
Intervention: Polaroid prints and 35 mm transparencies of equivalent quality
Number of subjects: 127
Study 3130124 — intervention group
Group type: EXPERIMENTAL
Intervention: Polaroid prints
Number of subjects: 127
Study 29068831 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced colloid solution
Number of subjects: 160
Study 29068831 — intervention group
Group type: COMPARATOR
Intervention: Balanced crystalloid solution
Number of subjects: 160
Study 27979752 — intervention group
Group type: EXPERIMENTAL
Intervention: Competence, autonomy, and relatedness interventions
Number of subjects: 0
Study 27979752 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 26630142 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care plus immunosuppressive therapy (immunosuppression group) for 3 years
Number of subjects: 162
Study 26630142 — intervention group
Group type: COMPARATOR
Intervention: Supportive care alone (supportive-care group) for 3 years
Number of subjects: 162
Study 23137271 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% NaOCl
Number of subjects: 20
Study 23137271 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 20
Study 21631622 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 75
Study 21631622 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 75
Study 18056742 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical NSAIDs
Number of subjects: 30
Study 18056742 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral NSAIDs
Number of subjects: 30
Study 18056742 — intervention group
Group type: EXPERIMENTAL
Intervention: General decision making
Number of subjects: 30
Study 18056742 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 30
Study 18056742 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adherence and efficacy
Number of subjects: 30
Study 16609086 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) 0.625 mg/d
Number of subjects: 10739
Study 16609086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10739
Study 12704534 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate foam 0.05%
Number of subjects: 279
Study 12704534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 11119091 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder infusion before trial of voiding (ToV)
Number of subjects: 75
Study 11119091 — intervention group
Group type: COMPARATOR
Intervention: Standard catheter removal
Number of subjects: 75
Study 8814495 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin therapy (45‐60 U/kg, three times a week)
Number of subjects: 13
Study 8814495 — intervention group
Group type: COMPARATOR
Intervention: Control group (haemodialysis patients without erythropoietin treatment)
Number of subjects: 13
Study 1415040 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-cell pertussis-component diphtheria-tetanus-pertussis vaccine (DTP)
Number of subjects: 40
Study 1415040 — intervention group
Group type: COMPARATOR
Intervention: Acellular pertussis-component diphtheria-tetanus-pertussis vaccine (APDT)
Number of subjects: 40
Study 4012381 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula diet (Ensure)
Number of subjects: 0
Study 4012381 — intervention group
Group type: COMPARATOR
Intervention: Low-residue, clear-liquid diet
Number of subjects: 0
Study 31868914 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 0
Study 31868914 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 31451349 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic Repair Group (ARG)
Number of subjects: 52
Study 31451349 — intervention group
Group type: COMPARATOR
Intervention: Open Repair Group (ORG)
Number of subjects: 52
Study 29661413 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine (1 μg kg-1)
Number of subjects: 0
Study 29661413 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine via atomiser (1 μg kg-1)
Number of subjects: 0
Study 29661413 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine by drops (1 μg kg-1)
Number of subjects: 0
Study 29661413 — intervention group
Group type: COMPARATOR
Intervention: Intranasal dexmedetomidine (both atomisation and drops)
Number of subjects: 0
Study 27923390 — intervention group
Group type: EXPERIMENTAL
Intervention: Early use of ≥64-slice CTCA as part of routine assessment
Number of subjects: 2424
Study 27923390 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2424
Study 24691606 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of tadalafil daily for 24 weeks
Number of subjects: 242
Study 24691606 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 242
Study 21962458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cylinder cast immobilisation for four weeks followed by rehabilitation
Number of subjects: 8
Study 21962458 — intervention group
Group type: COMPARATOR
Intervention: No immobilisation and early rehabilitation
Number of subjects: 8
Study 19332493 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat overfeeding (60% energy, +50% for 5 days)
Number of subjects: 26
Study 19332493 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 26
Study 19332493 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat overfeeding
Number of subjects: 26
Study 17764785 — intervention group
Group type: EXPERIMENTAL
Intervention: Boussignac CPAP
Number of subjects: 0
Study 17764785 — intervention group
Group type: COMPARATOR
Intervention: Bilevel PAP
Number of subjects: 0
Study 14711459 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken extract (CE) group, 70 mL/bottle, three times a day, providing 18 g protein from the 37th week of pregnancy to 3 days postpartum.
Number of subjects: 30
Study 14711459 — intervention group
Group type: COMPARATOR
Intervention: Control group, high protein supplement was restricted.
Number of subjects: 30
Study 12486650 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil-clonidine-propofol
Number of subjects: 0
Study 12486650 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil-propofol
Number of subjects: 0
Study 10423058 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 M HCl perfusion in GERD patients
Number of subjects: 48
Study 10423058 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful therapy (omeprazole or fundoplication)
Number of subjects: 48
Study 10423058 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid perfusion
Number of subjects: 48
Study 10423058 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical and surgical therapy
Number of subjects: 48
Study 10423058 — intervention group
Group type: COMPARATOR
Intervention: Saline perfusion
Number of subjects: 48
Study 8989404 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendon vibration at 20 Hz
Number of subjects: 0
Study 8989404 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendon vibration at 30 Hz
Number of subjects: 0
Study 8989404 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendon vibration at 40 Hz
Number of subjects: 0
Study 8989404 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendon vibration starting at movement onset (40 Hz)
Number of subjects: 0
Study 8989404 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendon vibration starting 5 s before movement onset and continuing throughout movement (40 Hz)
Number of subjects: 0
Study 8989404 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendon vibration starting 5 s before movement onset and stopping at movement onset (40 Hz)
Number of subjects: 0
Study 8989404 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendon vibration at 20 Hz (matching tasks)
Number of subjects: 0
Study 8989404 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendon vibration at 40 Hz (matching tasks)
Number of subjects: 0
Study 2160441 — intervention group
Group type: EXPERIMENTAL
Intervention: VLCD with dietary fibre (30 g/day)
Number of subjects: 22
Study 2160441 — intervention group
Group type: COMPARATOR
Intervention: VLCD without dietary fibre
Number of subjects: 22
Study 7031568 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin prophylaxis (5,000 micro sodium heparin subcutaneously every 12 hours)
Number of subjects: 32
Study 7031568 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heparin prophylaxis)
Number of subjects: 32
Study 6437372 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD‐TPN (15% dextrose, fat, and 5% amino acids)
Number of subjects: 88
Study 6437372 — intervention group
Group type: COMPARATOR
Intervention: CON‐TPN (25% dextrose and 4.25% amino acids)
Number of subjects: 88
Study 29294154 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A biliary strictures
Number of subjects: 65
Study 29294154 — intervention group
Group type: EXPERIMENTAL
Intervention: Type B biliary strictures
Number of subjects: 65
Study 29294154 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Type A and Type B biliary strictures
Number of subjects: 65
Study 26719058 — intervention group
Group type: EXPERIMENTAL
Intervention: mIPV2HD
Number of subjects: 233
Study 26719058 — intervention group
Group type: COMPARATOR
Intervention: IPV
Number of subjects: 233
Study 23098260 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory training (non-numerical)
Number of subjects: 51
Study 23098260 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory training (numerical)
Number of subjects: 51
Study 23098260 — intervention group
Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 51
Study 22234648 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-a-week supervised aerobic and resistance training plus exercise counselling (exercise group)
Number of subjects: 606
Study 22234648 — intervention group
Group type: COMPARATOR
Intervention: Counselling alone (control group)
Number of subjects: 606
Study 20138446 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron intake of 1.11 mg/kg/day (SD 0.06)
Number of subjects: 13
Study 18307851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough duration
Number of subjects: 807
Study 18307851 — intervention group
Group type: EXPERIMENTAL
Intervention: Children
Number of subjects: 807
Study 18307851 — intervention group
Group type: EXPERIMENTAL
Intervention: History of fever
Number of subjects: 807
Study 18307851 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted activities
Number of subjects: 807
Study 18307851 — intervention group
Group type: EXPERIMENTAL
Intervention: More severe symptoms
Number of subjects: 807
Study 14760090 — intervention group
Group type: EXPERIMENTAL
Intervention: gp100209-2M peptide immunization
Number of subjects: 35
Study 11499321 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐1 medium (Irvine Scientific)
Number of subjects: 182
Study 11499321 — intervention group
Group type: COMPARATOR
Intervention: IVF‐50 medium (Scandinavian IVF Science)
Number of subjects: 182
Study 9258614 — intervention group
Group type: EXPERIMENTAL
Intervention: Brush cytology
Number of subjects: 63
Study 9258614 — intervention group
Group type: COMPARATOR
Intervention: Impression cytology
Number of subjects: 63
Study 7942250 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol administration
Number of subjects: 0
Study 7942250 — intervention group
Group type: COMPARATOR
Intervention: Tonic water administration (placebo)
Number of subjects: 0
Study 3284831 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg piretanide once or twice daily
Number of subjects: 47
Study 3284831 — intervention group
Group type: COMPARATOR
Intervention: 50 mg hydrochlorothiazide plus 5 mg amiloride
Number of subjects: 47
Study 29971702 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training with HeartMath monitor and Quick Coherence technique
Number of subjects: 44
Study 29971702 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training with HeartMath Quick Coherence technique
Number of subjects: 44
Study 29971702 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study 26742065 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and physical activity intervention
Number of subjects: 46
Study 26742065 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 46
Study 24498968 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-treated asparagus extract (ETAS) at 200 mg/kg body weight
Number of subjects: 1
Study 24498968 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-treated asparagus extract (ETAS) at 1000 mg/kg body weight
Number of subjects: 1
Study 24498968 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-treated asparagus extract (ETAS) at 150 mg/d for 7 days
Number of subjects: 1
Study 24498968 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-treated asparagus extract (ETAS) at 0.125 mg/mL
Number of subjects: 1
Study 24498968 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-treated asparagus extract (ETAS) at 1.0 mg/mL
Number of subjects: 1
Study 24498968 — intervention group
Group type: COMPARATOR
Intervention: ETAS-untreated mice
Number of subjects: 1
Study 22217936 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine-guided ablation until dormant conduction is abolished
Number of subjects: 488
Study 22217936 — intervention group
Group type: COMPARATOR
Intervention: Standard PVI
Number of subjects: 488
Study 21198228 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT4CBT (computer-based cognitive-behavioral therapy)
Number of subjects: 77
Study 21198228 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 77
Study 18090049 — intervention group
Group type: EXPERIMENTAL
Intervention: nevirapine 400 mg once-daily (n = 31)
Number of subjects: 62
Study 18090049 — intervention group
Group type: COMPARATOR
Intervention: nevirapine 200 mg twice-a-day (n = 31)
Number of subjects: 62
Study 16120030 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 28
Study 16120030 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily insulin (MDI)
Number of subjects: 28
Study 11898480 — intervention group
Group type: EXPERIMENTAL
Intervention: New antiepileptic drugs (AEDs)
Number of subjects: 0
Study 11898480 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative studies of AEDs
Number of subjects: 0
Study 9923580 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice with 2 mg pranidipine
Number of subjects: 16
Study 9923580 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice with 2 mg pranidipine
Number of subjects: 16
Study 9923580 — intervention group
Group type: COMPARATOR
Intervention: Water with 2 mg pranidipine
Number of subjects: 16
Study 8087824 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50-200 mg daily)
Number of subjects: 11
Study 8087824 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN; 5 and 15 mg)
Number of subjects: 11
Study 8087824 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with captopril and ISDN
Number of subjects: 11
Study 8087824 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 11
Study 2676430 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal glucagon
Number of subjects: 0
Study 2676430 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular glucagon
Number of subjects: 0
Study 1103563 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenidol (1,1‐diphenyl‐4‐piperidino‐l‐butanol hydrochloride)
Number of subjects: 24
Study 1103563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30508863 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 16
Study 30508863 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic exercise
Number of subjects: 16